Life Extension Magazine®
HIV and AIDS: New Breakthroughs |
STOP THE PRESS: HIV Treatment ProtocolAs we were about to go to press with this issue of the magazine, preliminary findings were released indicating that various combinations of the anti-viral therapies (AZT, ddI, 3TC and Crixivan) along with a protease inhibitor showed remarkable success in 175 AIDS patients. In other studies using Crixivan (a chemical cousin to AZT), 13 of 22 patients had no detectable virus after five months; one patient on Crixivan had no detectable virus for two years. The cost of using these combination therapies was estimated at $11,400 a year. Based on these preliminary reports, we make the following recommendations:
Exciting New Studies Bring HopeTwo recent studies have indicated that non-toxic substances may inhibit HIV The January issue of Arthritis and Rheumatism reported that a quinine based drug dramatically decreased AIDS-associated arthritis, inhibited HIV replication, and had a positive effect on a immunity. Although the study involved 2 patients, a previous study on 40 patients drew the same conclusions. The beneficial effects of the bark of the cinchona tree (from which quinine drugs are made) have been known for thousands of years. Atabrine and Plaquenil are 2 quinine-based drugs. A study published in Blood shows that vitamin B, inhibits HIV in the test tube. And researchers in Florida have shown that DHEA inhibits FIV, the feline version of HIV, in the test tube. |